methyl 4-acetylamino-5-formyl-3-methoxybenzoate | 165592-49-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-acetylamino-5-formyl-3-methoxybenzoate
• 英文别名: Methyl 4-acetamido-3-formyl-5-methoxybenzoate
• CAS: 165592-49-4
• 化学式: C₁₂H₁₃NO₅
• 分子量: 251.239
• InChiKey: HVGHAEJPZIJPNO-UHFFFAOYSA-N

物化性质

• 沸点：
  455.8±45.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4-acetylamino-5-formyl-3-methoxybenzoate 在 sodium hydroxide 、 sodium hydride 作用下， 以 甲醇 为溶剂， 反应 97.0h， 生成 6-carboxy-8-methoxy-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o
• 作为产物：
  描述：

  3-甲氧基-4-氨基苯甲酸甲酯 在 盐酸 、 N-氯代丁二酰亚胺 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 17.5h， 生成 methyl 4-acetylamino-5-formyl-3-methoxybenzoate
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o

文献信息

• PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0636128A1

  公开（公告）日：1995-02-01
• US5591751A
  申请人：——

  公开号：US5591751A

  公开（公告）日：1997-01-07
• [EN] PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS<br/>[FR] UTILISATION DE PIPERAZINOCARBONYLCARBOSTYRILES COMME VASODILATATEURS PERIPHERIQUES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：WO1994019339A1

  公开（公告）日：1994-09-01

  (EN) The present invention provides novel peripheral vasodilating agents and novel carbostyril derivatives having peripheral vasodilating activity. Peripheral vasodilating agents containing, as the active ingredient, carbostyril derivatives represented by general formula (1) or salt thereof; and novel carbostyril derivatives which are included within the scope of the above-mentioned general formula.(FR) La présente invention concerne de nouveaux agents de vasodilatation périphérique et de nouveaux dérivés de carbostyrile ayant une activité de vasodilatation périphérique. Agents de vasodilatation périphérique contenant, comme ingrédient actif, des dérivés de carbostyrile représentés par la formule générale (1), ou sel tiré de ces dérivés; et nouveaux dérivés du carbostyrile, inclus dans ladite formule générale.
• Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives
  作者：Shuji Teramoto、Michinori Tanaka、Hiroshi Shimizu、Takafumi Fujioka、Fujio Tabusa、Takashi Imaizumi、Kenji Yoshida、Hiroyuki Fujiki、Toyoki Mori、Takumi Sumida、Michiaki Tominaga

  DOI：10.1021/jm020597o

  日期：2003.7.1

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.